Enoxaparin

Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19[1][2][3].

Product Specifications

CAS Number

[679809-58-6]

Product Name Alternative

PK 10169; Enoxaparin sodium

UNSPSC

12352005

Hazard Statement

H317

Target

Factor Xa; SARS-CoV; Thrombin

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/enoxaparin.html

Purity

Solubility

H2O : ≥ 100 mg/mL

Smiles

[Enoxaparin]

Precautions

H317

References & Citations

[1]Bai X, et al. Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. Sci Rep. 2022 Mar 25;12 (1) :5207. |[2]Župan Ž, et al. Effects of enoxaparin in the rat hippocampus following traumatic brain injury. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35 (8) :1846-56.|[3]Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May;5 (3) :387-99.